Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

MCAD deficiency in Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

  1. European expert consensus statement on therapeutic goals in Fabry disease

    Research output: Contribution to journalReviewResearchpeer-review

  2. Exercising with blocked muscle glycogenolysis: Adaptation in the McArdle mouse

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Development of hypomelanotic macules is associated with constitutive activated mTORC1 in tuberous sclerosis complex

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impaired Fat Oxidation During Exercise in Long-Chain Acyl-CoA Dehydrogenase Deficiency Patients and Effect of IV-Glucose

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. l-Carnitine Improves Skeletal Muscle Fat Oxidation in Primary Carnitine Deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Osteogenesis imperfecta and the teeth, eyes, and ears-a study of non-skeletal phenotypes in adults

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is the most common defect of fatty acid oxidation. Many countries have introduced newborn screening for MCADD, because characteristic acylcarnitines can easily be identified in filter paper blood spot samples by tandem mass spectrometry (MS/MS), because MCADD is a frequent disease, and because of the success of early treatment initiated before clinical symptoms have emerged. In Denmark we have screened 519,350 newborns for MCADD by MS/MS and identified 58 affected babies. The diagnosis of MCADD was confirmed in all 58 newborns by mutation analysis. This gives an incidence of MCADD detected by newborn screening in Denmark of 1/8954. In sharp contrast to this we found that the incidence of clinically presenting MCADD in Denmark in the 10 year period preceding introduction of MS/MS-based screening was only 1 in 39,691. This means that four times more newborns with MCADD are detected by screening than what is expected based on the number of children presenting clinically in an unscreened population. The mutation spectrum in the newborns detected by screening is different from that observed in clinically presenting patients with a much lower proportion of newborns being homozygous for the prevalent disease-causing c.985A>G mutation. A significant number of the newborns have genotypes with mutations that have not been observed in patients detected clinically. Some of these mutations, like c.199T>C and c.127G>A, are always associated with a milder biochemical phenotype and may cause a milder form of MCADD with a relatively low risk of disease manifestation, thereby explaining part of the discrepancy between the frequency of clinically manifested MCADD and the frequency of MCADD determined by screening. In addition, our data suggest that some of this discrepancy can be explained by a reduced penetrance of the c.985A>G mutation, with perhaps only 50% of c.985A>G homozygotes presenting with disease manifestations. Interestingly, we also report that the observed number of newborns identified by screening who are homozygous for the c.985A>G mutation is twice that predicted from the estimated carrier frequency. We therefore redetermined the carrier frequency in a new sample of 1946 blood spots using a new assay, but this only confirmed that the c.985A>G carrier frequency in Denmark is approximately 1/105. We conclude that MCADD is much more frequent than expected, has a reduced penetrance and that rapid genotyping using the initial blood spot sample is important for correct diagnosis and counseling.
Original languageEnglish
JournalMolecular Genetics and Metabolism
Volume106
Issue number2
Pages (from-to)175-88
Number of pages14
ISSN1096-7192
DOIs
Publication statusPublished - 2012

    Research areas

  • Acyl-CoA Dehydrogenase, Alleles, Base Sequence, Carnitine, Denmark, Family, Female, Genetic Association Studies, Genotype, Humans, Incidence, Infant, Infant, Newborn, Lipid Metabolism, Inborn Errors, Male, Mutation, Neonatal Screening, Phenotype, Tandem Mass Spectrometry

ID: 36437671